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Abstract
BACKGROUND: Black women have worse breast cancer survival after controlling for clinical 
factors, suggesting that treatment differences may contribute to poorer outcomes. Delays in 
initiating and completing treatment are one proposed mechanism.
METHODS: The Carolina Breast Cancer Study Phase III is a large population-based cohort of 
women with incident breast cancer. Study participants comprised black (n=1328) and white 
(n=1331) women with stage I-III disease whose treatment included surgery with or without 
adjuvant therapies. We employed a novel treatment pathway grouping to benchmark treatment 
duration (surgery only; surgery + chemotherapy; surgery + radiation; or all three). Models 
controlled for treatment pathway, age, and tumor characteristics, and demographic factors related 
to healthcare access. We performed exploratory analyses of the association between delays and 
cancer recurrence.
RESULTS: In fully adjusted analyses, blacks had 1.73 times higher odds of treatment initiation 
>60 days after diagnoses compared to whites (OR: 1.73, 95% CI: 1.04–2.90). Race was also 
associated with longer treatment duration. Blacks were also more likely to be in the highest 
quartile of treatment duration (OR: 1.69, 95% CI: 1.41, 2.02), even after adjustment for 
demographic and tumor characteristics (OR: 1.31, 95% CI: 1.04–1.64). A non-significant trend 
toward higher recurrence risk was observed for patients with delayed initiation (HR 1.44, 95% CI 
0.89–2.33) or longest duration (HR 1.17, 95% CI 0.87–1.59).
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CONCLUSIONS: Black women more often had delayed treatment initiation and longer duration 
than whites receiving similar treatment. Interventions that target access barriers may be needed to 
improve timely delivery of care.
Precis
Black women more often have delays across the breast cancer treatment continuum than whites 
receiving similar treatment. Interventions that target access barriers may be needed to improve 
timely delivery of care.
Keywords
breast cancer; health care disparities; minority health
Background
Despite comparable or lower incidence of breast cancer than White women in the United 
States, Black women have higher breast cancer mortality, a survival gap that has persisted 
for more than four decades.1–3 Survival differences between Black and White women are 
attributable in part to the greater proportion of hormone receptor- and HER2 receptor-
negative or “triple negative” cancers among young black women,1,4 more advanced stage3 
and higher grade at diagnosis,5 and other adverse tumor features in Black women.5–7 
However, the survival decrement that remains after accounting for tumor stage and subtype 
suggests that post-diagnosis factors also contribute to racial disparities in US breast cancer 
outcomes.8
Disparities in diagnostic and treatment patterns, including treatment delays, have been 
described for Black women, and may contribute to racial differences in breast cancer 
survival. Black women experience longer intervals than Whites between first symptom, 
screening, or consult and biopsy-proven diagnosis.9,10 Black women are also more likely to 
experience delays in surgical treatment after a new diagnosis than Whites.11912,1314,15 
Radiation is also delayed in Black women, and these delays appear to be explained in part 
by differences in geographic access to radiation facilities.1617 Black patients experience 
delays in initiating and completing chemotherapy,18–21 and experience longer time to 
initiation of appropriate endocrine therapy.22 Although differential insurance coverage may 
explain some of these differences, Black women are still more likely to experience 
delays9,11,12,16 and to fare worse12,18,19,23 after controlling for insurance type. 
Unfortunately, delays are particularly impactful on clinical outcomes of triple negative 
breast cancer, a subtype more common among Black women.18,23
Significant gaps exist in understanding the drivers of treatment delay across the continuum 
of cancer care. Although race, geography, insurance access, and other socioeconomic factors 
all have been individually implicated in treatment delays, the literature describing these 
patterns has several gaps. First, large studies of racial and geographic factors associated with 
treatment delay typically have relied on neighborhood-level characteristics rather than 
individual-level data on education and income, limiting the ability to account for the impact 
of socioeconomic status. Second, studies with more detailed information on individual 
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characteristics, such as chart reviews, generally focus on patients within a restricted 
geographic location or institution, where access may be relatively homogenous. Third, most 
studies assess only one fragmentary measure of treatment delay, such as time from diagnosis 
to surgery or time from surgery to radiation, rather than trying to understand more precisely 
how delays may be compounded across the care continuum. Finally, most studies focus on 
delays in initiation of treatment, rather than a broader consideration of the timeliness of 
completion of the entire treatment plan. A more complete understanding of how delays 
occur and in which patients, whether they accumulate for the same patients across the 
spectrum of cancer care, and how race and geographic factors interact in treatment delays, is 
needed.
The Carolina Breast Cancer Study offers is a population-based, minority-enriched study 
representing 44 urban and rural counties in North Carolina and includes detailed treatment 
data. The study’s Phase III population (CBS3) comprises 2,998 racially diverse women with 
newly diagnosed breast cancer in North Carolina, a state with a spectrum of urban and rural 
geographies and demographic heterogeneity. The study includes a wealth of patient-reported 
individual data on socioeconomic status, place of residence and locations of treatment, and 
detailed medical record abstraction of breast cancer treatments and dates. In this study, we 
examine the relationship between delays throughout the cancer care continuum, while 
considering stage, race, socioeconomic status, and geography as potential determinants, and 
using a novel benchmarking approach to assess treatment timeliness.
Methods
Data source and study population
Women eligible for CBCS3 were identified through the Rapid Case Ascertainment of the 
North Carolina Central Cancer Registry (NCCCR), and selected by randomized recruitment 
within four strata defined by race (African American (AA vs. non-AA) and age (<50 vs. 50+ 
years of age at diagnosis). Participants underwent extensive structured in-home baseline 
interviews with a trained nurse, during which anthropomorphic data and a germline DNA 
sample were also gathered. Women also consented to medical record review, from which 
detailed cancer treatment data were abstracted.
This analysis was restricted to women who i) were diagnosed with stage I-III cancers, ii) 
self-reported African American/Black or White race, and iii) underwent surgery for breast 
cancer within 18 months of diagnosis (n=2,761). To avoid confusion between primary 
treatment and treatment of early relapses, we restricted the analysis to patients without 
documented relapse within 18 months of diagnosis.
Covariate assessment
Putative predictors of treatment delay were ascertained from home-based structured 
interviews with a nurse. These covariates included age at diagnosis (<40, 40–49, 50–59, 60+ 
years), self-reported race (Black, White) educational attainment (<high school education, 
high school graduate-some college, college graduate or higher), annual family income (<
$20,000, $20-<50,000, $50,000+), insurance type (uninsured, any Medicaid, Medicare (no 
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Medicaid), private/other), marital status and county of residence. Since many counties had 
small numbers of cases, county of residence was grouped into nine Area Health Education 
Center (AHEC) regions. Tumor characteristics including stage at diagnosis, hormone 
receptor (HR) positivity, and human epidermal growth factor receptor 2 (HER2) positivity, 
were ascertained from pathology reports.
Outcome assessment
The primary outcomes of interest, delayed treatment initiation and prolonged treatment 
duration, were defined based on dates observed in the medical record. Treatment initiation 
was defined as the first treatment-directed surgery, radiation, or chemotherapy event 
observed after diagnosis. Time from diagnosis date to treatment initiation was measured in 
days and those exceeding 60 days were categorized as having ‘delayed initiation’. The 60 
day threshold was chosen based on clinical judgement and distribution of time to first 
treatment to represent a clinically significant and unusual delay in care, and based on prior 
research associating pre-operative intervals of greater than 60 days with survival decrements.
24
To assess timeliness of treatment completion, we characterized treatment duration as the 
interval between treatment initiation and the last day of the latest treatment observed in the 
medical record prior to a cancer recurrence. Given the chronic nature of maintenance 
biologic therapy for HER2+ disease (1 year duration) and adjuvant endocrine therapy (5–10 
year duration), these targeted therapies were not included in our assessment. Patients were 
classified into four treatment patterns: surgery only, surgery and radiation, surgery and 
chemotherapy, or all three modalities. Within each treatment group, a patient’s duration of 
treatment was benchmarked against other patients who received the same therapies. We 
calculated quartiles of treatment duration within each group and classified women who were 
above the 75th percentile of treatment duration compared to others in their group as having 
‘prolonged treatment duration’. Time to first recurrence was ascertained from medical 
records abstraction.
Statistical analysis
For descriptive analyses, chi-square tests utilizing CBCS3 randomized recruitment sampling 
weights were used to test whether covariate distributions differed by treatment timing. Log-
binomial and logistic regression models then were used to evaluate the relationship between 
race and delayed initiation and prolonged treatment duration. Three sets of models were 
performed: (1) minimally-adjusted models controlling only for age in 10-year age 
categories, and (2) models adjusted for age and demographic characteristics (marital status, 
income, education, insurance type, and AHEC region), and (3) models adjusted for age and 
demographic and tumor characteristics (stage, HR, HER2).
In exploratory analyses, we examined whether delayed initiation and treatment duration 
were associated with recurrence-free survival. Cox proportional hazards models were used 
with adjustment for HR and HER2 receptor status, grade, nodal status, size, and 10-year age 
group. Survival time was assessed beginning at 18 months because the full cohort was 
required to be recurrence-free at 18 months. For analysis of treatment duration, we 
Reeder-Hayes et al. Page 4













additionally excluded individuals who had continuous active treatment for more than 18 
months after diagnosis (n=18), because of the concern for undocumented recurrent disease 
driving the treatment plan, or who experienced a documented recurrence (n=108) and/or 
were lost to follow up (n=81) prior to 18 months from diagnosis.
Results
The analysis included 2,659 CBCS3 participants. The median time to treatment initiation 
was 24 days (interquartile range: 13–36). A total of 117 (4.4%) women initiated treatment 
more than 60 days after diagnosis. In bivariate analyses, women with delayed treatment 
initiation were significantly more likely to be black, unmarried, have lower income, be 
uninsured or insured through Medicaid, and to have later stages at diagnosis (Table 1). They 
also were more likely to live in the Charlotte AHEC region, and less likely to live in the 
Wake AHEC region; these regions correspond to the two largest metropolitan regions in the 
study catchment area. Those who had delayed treatment initiation were more likely to 
receive surgery only, and were less likely to receive all modalities.
The distribution of treatment durations, measured from the first day of first treatment to the 
last day of final treatment, is presented by treatment group (Figure 1). There was substantial 
variation in treatment duration within each treatment group. As expected, increasing number 
of treatment modalities was associated with longer treatment duration.
In bivariate analyses, women with the longest treatment durations (highest quartile) 
compared to others in their own treatment pathway were more likely to be black, younger, 
lower income, uninsured or have Medicaid, less educated, higher stage at diagnosis, and 
have HER2 positive disease (Table 1). The association with HER2-positive was observed 
despite the fact that maintenance HER2-directed therapy was not considered as part of the 
treatment duration. Delayed initiation did not appear to be strongly associated with 
prolonged duration in bivariate analysis (X2 p-value 0.29).
Multivariable-adjusted associations between race and treatment delay (60+ days after 
diagnosis) and treatment duration (highest quartile) are summarized in Table 2. Black 
women more frequently experienced delayed treatment (age-adjusted Odds ratio (OR): 2.50, 
95% confidence interval (CI): 1.66, 3.77). Adjustment for demographic characteristics and 
geographic region of residence attenuated this difference, but significantly higher frequency 
of delay among black women persisted. Adjustment for tumor characteristics only slightly 
attenuated the association; in the fully adjusted model black women had almost twice the 
frequency of delayed initiation compared to white women (OR: 1.73, 95% CI: 1.04–2.90).
Race was also associated with treatment duration. In age-adjusted models, black women 
were significantly more likely to be in the highest quartile of treatment duration compared to 
white women (OR: 1.69, 95% CI: 1.41, 2.02). Adjustment for demographic characteristics 
and geographic region of residence slightly attenuated this association, as did additional 
adjustment for tumor characteristics. However, after adjustment for both demographic and 
tumor characteristics, Black women remained more likely to experience the longest 
treatment durations (OR: 1.31, 95% CI: 1.04–1.64).
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To assess the impact of delayed initiation and treatment prolongation, we performed 
exploratory analyses of the association between delayed initiation, prolonged duration and 
recurrence-free survival (Figure 2). After adjustment for age, receptor status, grade, and 
tumor size, a non-significant trend association with recurrence was suggested for patients 
with delayed initiation (HR: 1.44, 95% CI: 0.89, 2.33) or longest quartile of duration (HR 
1.17, 95% CI 0.87–1.59) compared to those receiving timely care.
Discussion
In this large population-based cohort of racially diverse patients with newly diagnosed non-
metastatic breast cancer, we found that compared to White women, Black women with 
similar treatment plans were more likely to experience delays in treatment initiation and 
longer treatment duration. Interestingly, the effect of urban geography was variable by the 
particular metropolitan area, suggesting that the effect of urban geography may vary 
depending on other characteristics of local health services. Interesting, delayed initiation was 
not strongly associated with prolonged treatment duration, suggesting that different patients 
may be at risk for delays at different points on the care continuum.
Our findings add to recent work from the National Comprehensive Cancer Network, the 
National Cancer Database, and medical chart reviews that report longer times from symptom 
onset to diagnosis,9 diagnosis to surgery25 and from diagnosis to adjuvant chemotherapy26 
for Black patients, and provide a novel approach to benchmarking treatment timeliness 
against other patients with similar treatment plans. Our data also suggest a trend toward 
increased recurrence associated with both delayed initiation and prolonged duration. These 
findings supplement earlier research that delays in initiation of surgical treatment beyond 60 
days24, as well as delays in time between surgery and initiation of chemotherapy18,23 are 
associated with decrements in breast cancer survival.
It has been noted that therapeutically appropriate interventions, including breast 
reconstruction and gene expression profile testing, can drive some treatment delays.26; 
however, given that reconstruction27–29 and gene expression profile testing are used at 
similar rates30 or lower rates31–34 among Black women, and that complications of breast 
reconstruction are similar across race35,36, such clinically appropriate delays are unlikely to 
explain the racial disparities we observed. Some previous literature has suggested that racial 
disparities in breast cancer treatment quality and timeliness may partially be explained by 
the characteristics of the institutions at which minority patients seek care,37,38, their 
insurance status, and/or the distribution of minority patients in geographic areas with lower 
access or longer distance to care.16,39 However, our study suggests that after controlling for 
these aspects using high-quality individual-level data, race remains an independent predictor 
of delay.
A number of additional factors, outside the scope of this analysis, may vary by race and 
impact treatment timeliness, including difficulty with transportation or sick leave, 
affordability of shared costs, distrust of medical providers, or toxicity experiences. We have 
recently reported greater financial toxicity of breast cancer among Black women.40 Other 
sources suggest that toxicities of radiation and chemotherapy, which could potentially 
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prolong therapy, are more common among Black women.41–44 Thus, there are several 
barriers not measured in this study that warrant future investigation.
This study has a number of strengths, including a racially diverse cohort with detailed 
information regarding timing of treatments and sociodemographic data, and an analytic 
approach that copes with clinically appropriate differences in treatment trajectories. We also 
recognize some limitations of our analysis. AHEC region was used as a gross measure of 
health care system factors within a geographic region, but does not control for all 
characteristics of oncology care in a given area. We did not adjudicate the clinical 
appropriateness of delays. Finally, while we did examine the relationship between delays 
and recurrence in exploratory analyses, CBCS3 has a limited follow up (median 5.5 years at 
this analysis), and longer follow-up is needed to evaluate long term impact of delays 
particularly among HR+ cases, where risk of distant recurrence persists for at least two 
decades after diagnosis.45
In summary, we found that after accounting for geographic, insurance, demographic, and 
disease characteristics, as well as the complexity of the treatment plan, Black women 
remained more likely than Whites to experience delays in initiation and completion of 
primary breast cancer treatment. Our findings of treatment timeliness disparities are 
particularly troubling given that Black women are more likely to be diagnosed at advanced 
stages and are disproportionately affected by biologically aggressive breast cancer 
subtypes4,7 associated with survival decrements after even brief delays (>30 days) in 
adjuvant therapy.18 The combination of delayed diagnosis, biologically aggressive disease, 
and treatment delays across the care continuum underscore the complexity of racial 
disparities in breast cancer and suggest multifactorial strategies are required to reduce breast 
cancer disparities. Interventions such as targeted patient navigation aimed at overcoming 
barriers to treatment may be worthy of investigation as means to forestall treatment delays.
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Distribution of Treatment Duration by Treatment Group
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Unadjusted recurrence-free survival by timeliness of initiation (A) and treatment duration 
(B), beginning from 60-day (A) or 18 month (B) landmarks.
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Table 1.
Cohort demographics by time to treatment initiation and treatment duration quartile.













Race N (%) N(%)
<0.0001
N (%) N (%)
<0.0001 White 1297 (51.0) 34 (29.1) 1066 (53.3) 265 (40.3)
 Black 1245 (49.0) 83 (70.9) 935 (46.7) 393 (59.7)
Age
0.4222 0.0180
 <40 294 (11.6) 13 (11.1) 230 (11.5) 77 (11.7)
 40–49 949 (37.3) 43 (36.8) 715 (35.7) 277 (42.1)
 50–59 568 (22.3) 33 (28.2) 457 (22.8) 144 (21.9)
 60–74 731 (28.8) 28 (23.9) 599 (29.9) 160 (24.3)
Marital status
0.0043 0.0197 Unmarried 1087 (42.8) 69 (59.0) 840 (42.0) 316 (48.0)
 Married 1455 (57.2) 48 (41.0) 1161 (58.0) 342 (52.0)
Income
0.0039 <0.0001
 <$20,000 524 (24.7) 41 (43.6) 363 (21.8) 202 (36.7)
 $20–50,000 459 (21.7) 20 (21.3) 351 (21.1) 128 (23.3)
 >$50,000 1137 (53.6) 33 (35.1) 950 (57.1) 220 (40.0)
 Missing 422 23 337 108
Primary insurance
0.0269 <0.0001
 Uninsured 136 (5.4) 12 (10.3) 98 (4.9) 50 (7.6)
 Medicaid 365 (14.4) 32 (27.6) 234 (11.7) 163 (24.8)
 Medicare 485 (19.1) 18 (15.5) 393 (19.7) 110 (16.7)
 Private/other 1555 (61.2) 54 (46.6) 1274 (63.7) 335 (50.9)
 Missing 1 1 2 0
Education
0.4211 0.0018
 <HS 1338 (52.6) 56 (47.9) 1027 (51.3) 367 (55.8)
 HS-Some college 1010 (39.7) 48 (41.0) 837 (41.8) 221 (33.6)
 College+ 194 (7.6) 13 (11.1) 137 (6.9) 70 (10.6)
AHEC region
0.0472 <0.0001
 UNC-Chapel Hill 169 (6.7) 10 (8.6) 151 (7.6) 28 (4.3)
 Area L 101 (4.0) 3 (2.6) 70 (3.5) 34 (5.2)
 Charlotte 484 (19.0) 35 (29.9) 409 (20.4) 110 (16.7)
 Eastern 255 (10.0) 11 (9.4) 170 (8.5) 96 (14.6)
 Greensboro 332 (13.1) 21 (18.0) 255 (12.7) 98 (14.9)
 Northwest 308 (12.1) 17 (14.5) 249 (12.4) 76 (11.6)
 South East 137 (5.4) 6 (5.1) 113 (5.7) 30 (4.6)
 Southern 206 (8.1) 3 (2.6) 147 (7.4) 62 (9.4)
 Wake 550 (21.6) 11 (9.4) 437 (21.8) 124 (18.8)
Stage 0.0470 <0.0001
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 I 1140 (44.9) 41 (35.0) 941 (47.0) 240 (36.5)
 II 1059 (41.7) 60 (51.3) 825 (41.2) 294 (44.7)
 III 343 (13.5) 16 (13.7) 235 (11.7) 124 (18.8)
HR status
0.4726 0.4982
 Negative 602 (23.9) 20 (17.5) 467 (23.6) 155 (23.9)
 Positive 1913 (76.1) 94 (82.5) 1514 (76.4) 493 (76.1)
 Missing 27 3 20 10
HER2 status
0.7684 0.0121
 Negative 2095 (83.4) 98 (85.2) 1685 (85.1) 508 (78.4)
 Positive 418 (16.6) 17 (14.8) 295 (14.9) 140 (21.6)




 Surg. only 326 (12.8) 26 (22.2) -- --
 Surg. + rad. 604 (23.8) 28 (23.9) -- --
 Surg. + chemo. 343 (13.5) 21 (18.0) -- --
 All 1269 (49.9) 42 (35.9) -- --
Delayed initiation --
0.2915 No -- -- 1917 (95.8) 625 (95.0)
 Yes -- -- 84 (4.2) 33 (5.0)
*
Weighted for CBCS3 sampling probabilities.
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Table 2.
Odds ratios (and 95% confidence intervals) for the association between race and treatment initiation and 
duration.
Age-adjusted Adjusted for demographics* Fully adjusted*
Initiation >60 days 2.50 (1.66, 3.77) 1.80 (1.09–2.97) 1.73 (1.04–2.90)
Q4 duration 1.69 (1.41, 2.02) 1.33 (1.07–1.66) 1.31 (1.04–1.64)
*
Additionally adjusted for income, education, AHEC region, marital status and insurance status
**
Additionally adjusted for stage, and HER2 and HR status
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